74 related articles for article (PubMed ID: 28425130)
1. Histological grading based on poorly differentiated clusters is predictive of tumour response and clinical outcome in rectal carcinoma treated with neoadjuvant chemoradiotherapy.
Reggiani Bonetti L; Lionti S; Domati F; Pagliani G; Mattioli E; Barresi V
Histopathology; 2017 Sep; 71(3):393-405. PubMed ID: 28425130
[TBL] [Abstract][Full Text] [Related]
2. A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial.
Battersby NJ; Dattani M; Rao S; Cunningham D; Tait D; Adams R; Moran BJ; Khakoo S; Tekkis P; Rasheed S; Mirnezami A; Quirke P; West NP; Nagtegaal I; Chong I; Sadanandam A; Valeri N; Thomas K; Frost M; Brown G
Trials; 2017 Aug; 18(1):394. PubMed ID: 28851403
[TBL] [Abstract][Full Text] [Related]
3. Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma.
Tan BR; Thomas F; Myerson RJ; Zehnbauer B; Trinkaus K; Malyapa RS; Mutch MG; Abbey EE; Alyasiry A; Fleshman JW; McLeod HL
J Clin Oncol; 2011 Mar; 29(7):875-83. PubMed ID: 21205745
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of tumour-infiltrating CD8+ lymphocytes in rectal cancer after neoadjuvant chemoradiation: is indoleamine-2,3-dioxygenase (IDO1) a friend or foe?
Schollbach J; Kircher S; Wiegering A; Seyfried F; Klein I; Rosenwald A; Germer CT; Löb S
Cancer Immunol Immunother; 2019 Apr; 68(4):563-575. PubMed ID: 30671614
[TBL] [Abstract][Full Text] [Related]
5. Utility of rectoscopy in the assessment of response to neoadjuvant treatment for locally advanced rectal cancer.
Lopez-Lopez V; Abrisqueta J; Lujan J; Hernandez Q; Ono A; Parrilla P
Saudi J Gastroenterol; 2016; 22(2):148-53. PubMed ID: 26997222
[TBL] [Abstract][Full Text] [Related]
6. Molecular diagnosis of response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer.
Chen Z; Duldulao MP; Li W; Lee W; Kim J; Garcia-Aguilar J
J Am Coll Surg; 2011 Jun; 212(6):1008-1017.e1. PubMed ID: 21458303
[TBL] [Abstract][Full Text] [Related]
7. Retrospective Evaluation of the Efficacy of Total Neoadjuvant Therapy and Chemoradiotherapy Neoadjuvant Treatment in Relation to Surgery in Patients with Rectal Cancer.
Bratu LD; Schenker M; Stovicek PO; Schenker RA; Mehedințeanu AM; Berisha TC; Donoiu A; Mogoantă SȘ
Medicina (Kaunas); 2024 Apr; 60(4):. PubMed ID: 38674302
[No Abstract] [Full Text] [Related]
8. Predictive value of FCGBP expression for treatment response and survival in rectal cancer patients undergoing chemoradiotherapy.
Su YT; Chen CH; Kang JW; Kuo HY; Yang CC; Tian YF; Yeh CF; Chou CL; Chen SH
Aging (Albany NY); 2024 May; 16(9):7889-7901. PubMed ID: 38709264
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral Budding and CD8-Positive T-cell Density in Pretreatment Biopsies as a Predictor of Response to Neoadjuvant Chemoradiotherapy in Advanced Rectal Cancer.
Sano S; Akiyoshi T; Yamamoto N; Hiyoshi Y; Mukai T; Yamaguchi T; Nagasaki T; Taketomi A; Fukunaga Y; Kawachi H
Clin Colorectal Cancer; 2023 Dec; 22(4):411-420.e1. PubMed ID: 37516615
[TBL] [Abstract][Full Text] [Related]
10. Complete response to neoadjuvant chemoradiotherapy in rectal cancer is associated with RAS/AKT mutations and high tumour mutational burden.
Stockton JD; Tee L; Whalley C; James J; Dilworth M; Wheat R; Nieto T; ; Geh I; Barros-Silva JD; Beggs AD
Radiat Oncol; 2021 Jul; 16(1):129. PubMed ID: 34256782
[TBL] [Abstract][Full Text] [Related]
11. When is neoadjuvant chemotherapy indicated in rectal neuroendocrine tumors? An analysis of the National Cancer Database.
Gefen R; Emile SH; Horesh N; Garoufalia Z; Freund MR; Wexner SD
Tech Coloproctol; 2024 May; 28(1):56. PubMed ID: 38772962
[TBL] [Abstract][Full Text] [Related]
12. Rectal cancer in Luxembourg : a national population-based data report, 1988-1998.
Scheiden R; Sand J; Weber J; Turk P; Wagener Y; Capesius C
BMC Cancer; 2003 Oct; 3():27. PubMed ID: 14567762
[TBL] [Abstract][Full Text] [Related]
13. Modified neoadjuvant rectal score as a novel prognostic model for rectal cancer patients who underwent chemoradiotherapy.
Kawai K; Ozaki K; Nakano D; Dejima A; Ise I; Nakamori S; Kato H; Natsume S; Takao M; Yamaguchi T; Ishihara S
Int J Clin Oncol; 2024 Apr; ():. PubMed ID: 38592641
[TBL] [Abstract][Full Text] [Related]
14. Tumour budding as a prognostic biomarker in biopsies and resections of neoadjuvant-treated rectal adenocarcinoma.
Aherne S; Donnelly M; Ryan ÉJ; Davey MG; Creavin B; McGrath E; McCarthy A; Geraghty R; Gibbons D; Nagtegaal I; Lugli A; Kirsch R; Martin ST; Winter DC; Sheahan K;
Histopathology; 2024 Apr; ():. PubMed ID: 38629323
[TBL] [Abstract][Full Text] [Related]
15. Identification of unique rectal cancer-specific subtypes.
Kisakol B; Matveeva A; Salvucci M; Kel A; McDonough E; Ginty F; Longley DB; Prehn JHM
Br J Cancer; 2024 May; 130(11):1809-1818. PubMed ID: 38532103
[TBL] [Abstract][Full Text] [Related]
16. Identification of tumour regression in neoadjuvantly treated pancreatic cancer is based on divergent and nonspecific criteria.
Holm MB; Lenggenhager D; Detlefsen S; Sántha P; Verbeke CS
Histopathology; 2024 Jul; 85(1):171-181. PubMed ID: 38571446
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Implications of the Immunoscore in Patients with Colorectal Cancer.
El Sissy C; Kirilovsky A; Zeitoun G; Marliot F; Haicheur N; Lagorce-Pagès C; Galon J; Pagès F
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33805758
[TBL] [Abstract][Full Text] [Related]
18. ASO Visual Abstract: Assessing Endoscopic Response in Locally Advanced Rectal Cancer Treated with Total Neoadjuvant Therapy: Development and Validation of a Highly Accurate Convolutional Neural Network.
Williams H; Thompson HM; Lee C; Rangnekar A; Gomez JT; Widmar M; Wei IH; Pappou EP; Nash GM; Weiser MR; Paty PB; Smith JJ; Veeraraghavan H; Garcia-Aguilar J
Ann Surg Oncol; 2024 Jun; ():. PubMed ID: 38851637
[No Abstract] [Full Text] [Related]
19. Early Age of Onset Is an Independent Predictor for a Worse Response to Neoadjuvant Therapies in Sporadic Rectal Cancer Patients.
Foppa C; Maroli A; Luberto A; La Raja C; Spaggiari P; Bonifacio C; De Zanet S; Montorsi M; Piscuoglio S; Terracciano LM; Santoro A; Spinelli A
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509411
[TBL] [Abstract][Full Text] [Related]
20. H3K27me3 Immunohistochemical Loss Predicts Lower Response to Neo-Adjuvant Chemo-Radiotherapy in Rectal Carcinoma.
Ammendola S; Caldonazzi N; Rizzo PC; Turri G; Pedrazzani C; Barresi V
Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
